About Almac Group
Almac Group is a company based in Craigavon (United Kingdom) founded in 2001. Almac Group has raised $338.8 million across 15 funding rounds from investors including Gates Foundation, European Union and Invest Northern Ireland. Almac Group has completed 2 acquisitions, including Arran Chemical and BioClin Labs. Almac Group offers products and services including Genomic Services, API Development, and Clinical Trial Services. Almac Group operates in a competitive market with competitors including Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals, Aurobindo Pharma and Asymchem, among others.
- Headquarter Craigavon, United Kingdom
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Almac Group Limited
- Date of Incorporation 20 Sep, 2001
- Jurisdiction CRAIGAVON
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$338.8 M (USD)
in 15 rounds
-
Latest Funding Round
$416.67 K (USD), Grant
Sep 06, 2022
-
Investors
Gates Foundation
& 4 more
-
Employee Count
Not available
-
Investments & Acquisitions
Arran Chemical
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Almac Group
Almac Group offers a comprehensive portfolio of products and services, including Genomic Services, API Development, and Clinical Trial Services.
Offers testing and analysis for biomarkers in clinical trials
Provides manufacturing solutions for drug substances
Manages supply and logistics for trials
People of Almac Group
Unlock access to complete
Unlock access to complete
Funding Insights of Almac Group
Almac Group has successfully raised a total of $338.8M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $416.67 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Almac Group
Almac Group has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Gates Foundation, European Union and Invest Northern Ireland.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Foundation fund focused on science & technology in Ireland
|
Locked | Locked | Locked | |
|
Business support and investment attraction services are provided to enterprises.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Almac Group
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Almac Group
Almac Group has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Arran Chemical and BioClin Labs.
Investment portfolio details for Almac Group
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
GLP and cGMP certified contract research laboratory
|
Locked | Locked | 2003 | Locked | |
|
Fine chemical company specializing in the development of products for a wide range of industries
|
Locked | Locked | 1984 | Locked |
Complete acquisition details for Almac Group
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Almac Group
Detailed financials for Almac Group
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Almac Group Comparisons
Peer comparison for Almac Group
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Almac Group
Almac Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals, Aurobindo Pharma and Asymchem, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of Almac Group
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Almac Group
Complete news archive for Almac Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Almac Group
Almac Group was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Almac Group is headquartered in Craigavon, United Kingdom. It is registered at Craigavon, Northern Ireland, United Kingdom.
Alan Armstrong is the current CEO of Almac Group.
Almac Group is a funded company, having raised a total of $338.8M across 15 funding rounds to date.
Almac Group was founded in 2001 and operates as a contract development and manufacturing organization in the biopharmaceutical sector. Services including biomarker discovery, API production, formulation development, clinical trial supplies, companion diagnostics, analytical support, and commercial manufacturing are provided. Facilities are maintained in Europe, North America, and Asia, with headquarters located in Craigavon, United Kingdom.
Almac Group's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.
Almac Group offers Genomic Services, API Development, and Clinical Trial Services.
Almac Group has made 2 acquisitions, including Arran Chemical, and BioClin Labs.
Almac Group has 5 investors. Key investors include Gates Foundation, European Union, Invest Northern Ireland, Genomic Health, and Science Foundation Ireland.
The valuation of Almac Group is $373.1M as of May 2019.